Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Essex Bio-Technology ( (HK:1061) ).
Essex Bio-Technology’s wholly owned subsidiary Majeton Pte Ltd has signed an exclusive distribution agreement with Osteopore International to market Osteopore’s 3D‑printed biomimetic and bioresorbable dental, orthodontic and maxillofacial implants in mainland China, Hong Kong and Macau. The deal, with an expected value exceeding RMB12 million including upfront, milestone and product supply payments, marks a strategic milestone for Essex Bio-Technology’s push into the stomatology market and broadens its product portfolio in oral and facial treatments, underpinning the Group’s drive for sustainable growth in the Chinese healthcare market.
The most recent analyst rating on (HK:1061) stock is a Hold with a HK$4.50 price target. To see the full list of analyst forecasts on Essex Bio-Technology stock, see the HK:1061 Stock Forecast page.
More about Essex Bio-Technology
Essex Bio-Technology Limited, incorporated in the Cayman Islands and listed in Hong Kong, operates in the biotechnology and medical products space, with a focus on therapeutic and medical solutions in China and the broader Greater China region. Through its subsidiaries, the Group is expanding its presence in specialized healthcare segments, including stomatology, by distributing advanced dental, orthodontic and maxillofacial products.
Average Trading Volume: 633,954
Technical Sentiment Signal: Buy
Current Market Cap: HK$2.44B
See more insights into 1061 stock on TipRanks’ Stock Analysis page.